Drug Sponsors

Allergan to acquire Naurex

Monday, July 27, 2015

Allergan, a global pharmaceutical company based in Dublin, has agreed to acquire Naurex, an Evanston, Ill.-based clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, in an all-cash transaction. Allergan will acquire Naurex for a $560 million, up-front payment, $460 million of which is payable upon the closing of the acquisition, as well as potential R&D success-based and sales-threshold milestone payments. 

[Read More]

Pfizer expands Cambridge Kendall Square research facility

Friday, July 24, 2015

Pfizer has expanded its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus.With this expansion, Pfizer has leased the full 500,000 square feet at 610 Main St. in Kendall Square in Cambridge, Mass. This space will continue to house the R&D activities that relocated to the building in 2014, and will enable the consolidation of Pfizer’s three other leased spaces in Cambridge into the one campus.

[Read More]

Tekmira changes name to Arbutus Biopharma, a hepatitis B solutions company

Wednesday, July 22, 2015

Tekmira Pharmaceuticals, headquartered in Vancouver, Canada, plans to change its corporate name to Arbutus Biopharma, a therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), to be effective on or before Aug. 3. The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the singular goal of delivering a cure for chronic HBV. The combined entity currently fields a large portfolio of HBV product candidates in the industry.

[Read More]